News

Cadence Adds New Class 7 (10,000) Cleanroom in Connecticut

Cadence, Inc., a leading contract manufacturer of medical devices, announced today the completion of a certified International Organization for Standardization (ISO) Class 7 (10,000) cleanroom at its Connecticut manufacturing facility.  The new cleanroom is dedicated to the production of innovative medical device components and subassemblies.

“The cleanroom opens the door to new, exciting opportunities for our manufacturing facility,” stated Chris Haddad, the Director of Operations at Cadence’s Connecticut facility.  “Adding the new cleanroom and citric passivation allows us to expand our service offerings for existing and new customers, as well as streamlines our supply chain, reduces costs, and complements our laser processing expertise.”

The new cleanroom further enhances Cadence’s portfolio as a leading, vertically integrated contract manufacturing partner of medical devices worldwide.  Cadence now offers certified cleanroom manufacturing at three of its facilities for maximum customer flexibility.

Located in Suffield, the Connecticut facility is dedicated to advanced laser processing technologies.  Virtually tour Cadence’s Connecticut facility here.

Read more here.

Recent News

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients

08/14/2026

Transforming the finance function in life sciences: Empower scalable growth

Life sciences companies operate in one of the most complex business environments. Long R&D timelines, limited early-stage revenue, and dependence on external funding create a financial landscape where every decision carries strategic weight. In this context, finance is not a back-office function. It is an operational engine that drives whether a company survives, scales, or